Robert Gould Sells 15,000 Shares of Fulcrum Therapeutics (NASDAQ:FULC) Stock

Fulcrum Therapeutics, Inc. (NASDAQ:FULC) Director Robert Gould sold 15,000 shares of the business’s stock in a transaction dated Wednesday, November 19th. The shares were sold at an average price of $11.03, for a total value of $165,450.00. Following the completion of the transaction, the director owned 484,864 shares in the company, valued at $5,348,049.92. This trade represents a 3.00% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link.

Fulcrum Therapeutics Price Performance

FULC opened at $11.29 on Friday. The company has a market capitalization of $611.01 million, a PE ratio of -9.57 and a beta of 3.02. Fulcrum Therapeutics, Inc. has a fifty-two week low of $2.32 and a fifty-two week high of $12.19. The business has a 50-day moving average of $8.86 and a 200-day moving average of $7.57.

Fulcrum Therapeutics (NASDAQ:FULC) last announced its quarterly earnings results on Wednesday, October 29th. The company reported ($0.31) EPS for the quarter, missing the consensus estimate of ($0.29) by ($0.02). On average, equities research analysts expect that Fulcrum Therapeutics, Inc. will post -0.16 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

A number of research analysts have recently weighed in on the stock. Piper Sandler restated an “overweight” rating and set a $16.00 price target (up previously from $12.50) on shares of Fulcrum Therapeutics in a report on Thursday, October 30th. HC Wainwright restated a “buy” rating and set a $12.00 target price on shares of Fulcrum Therapeutics in a report on Monday, October 20th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Fulcrum Therapeutics in a research report on Wednesday, October 8th. Royal Bank Of Canada increased their price objective on Fulcrum Therapeutics from $5.00 to $7.00 and gave the company a “sector perform” rating in a report on Thursday, October 30th. Finally, Wall Street Zen lowered Fulcrum Therapeutics from a “hold” rating to a “sell” rating in a report on Saturday, November 1st. One equities research analyst has rated the stock with a Strong Buy rating, four have issued a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the company’s stock. According to MarketBeat, the stock currently has an average rating of “Moderate Buy” and an average price target of $13.00.

Institutional Investors Weigh In On Fulcrum Therapeutics

Several hedge funds and other institutional investors have recently made changes to their positions in the business. Acadian Asset Management LLC lifted its position in shares of Fulcrum Therapeutics by 865.0% during the 1st quarter. Acadian Asset Management LLC now owns 344,561 shares of the company’s stock worth $989,000 after purchasing an additional 308,854 shares during the last quarter. Jacobs Levy Equity Management Inc. bought a new position in Fulcrum Therapeutics in the 1st quarter worth approximately $425,000. Exome Asset Management LLC lifted its holdings in shares of Fulcrum Therapeutics by 143.0% during the first quarter. Exome Asset Management LLC now owns 689,137 shares of the company’s stock worth $1,985,000 after buying an additional 405,538 shares during the last quarter. Strs Ohio bought a new stake in shares of Fulcrum Therapeutics in the first quarter valued at approximately $263,000. Finally, XTX Topco Ltd bought a new stake in shares of Fulcrum Therapeutics in the first quarter valued at approximately $144,000. 89.83% of the stock is owned by institutional investors and hedge funds.

About Fulcrum Therapeutics

Fulcrum Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on developing products for improving the lives of patients with genetically defined diseases in the areas of high unmet medical need in the United States. Its product candidates are losmapimod, a small molecule for the treatment of facioscapulohumeral muscular dystrophy is under phase III clinical trial; and pociredir, a fetal hemoglobin inducer for the treatment of sickle cell disease and beta-thalassemia is under phase I clinical trial.